title: Health outcomes and cost-effectiveness of certolizumab pegol in the treatment of Crohn's disease.
abstract: Crohn's disease (CD) causes chronic inflammation of the gastrointestinal tract and leads to fluctuations between active disease and remission. Certolizumab pegol is one of the newer biological treatments for patients with moderate-to-severe CD. Certolizumab pegol was shown to be effective in CD patients achieving response and remission in both randomized and non-randomized studies, and is an alternative biological treatment for CD. The available data show that certolizumab pegol achieves similar therapeutic efficacy and health-related quality of life scores in CD patients as the other biological agents, but at a higher cost, if dose escalation of other biologics is not considered. Considering subcutaneous self-administration, and lower number and frequency of injections, patients may prefer certolizumab pegol over the other biological treatments.
authors.affiliation: University of Arizona College of Pharmacy, 1295 N. Martin Ave. Tucson, AZ 85721-0202, USA.
authors.forename: Jill M
authors.initials: JM
authors.lastname: Augustine
authors.forename: Jeannie K
authors.initials: JK
authors.lastname: Lee
authors.forename: Edward P
authors.initials: EP
authors.lastname: Armstrong
mesh_terms: D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000191:economics* / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage / Q000009:adverse effects / Q000191:economics* / Q000627:therapeutic use*; D000068582:Certolizumab Pegol; D003362:Cost-Benefit Analysis; D003424:Crohn Disease / Q000175:diagnosis / Q000188:drug therapy* / Q000191:economics*; D016527:Drug Costs; D005765:Gastrointestinal Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000191:economics* / Q000627:therapeutic use*; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000008:administration & dosage / Q000009:adverse effects / Q000191:economics* / Q000627:therapeutic use*; D007279:Injections, Subcutaneous; D018803:Models, Economic; D057240:Patient Preference / Q000191:economics; D011092:Polyethylene Glycols / Q000008:administration & dosage / Q000009:adverse effects / Q000191:economics* / Q000627:therapeutic use*; D011788:Quality of Life; D012074:Remission Induction; D012646:Self Administration; D012720:Severity of Illness Index; D016896:Treatment Outcome
chemical_list: D000893:Anti-Inflammatory Agents; D061067:Antibodies, Monoclonal, Humanized; D005765:Gastrointestinal Agents; D007140:Immunoglobulin Fab Fragments; D011092:Polyethylene Glycols; D000068582:Certolizumab Pegol
keywords: Crohn’s disease; biologics; certolizumab pegol; inflammatory bowel disease